Early and late asthmatic reaction after allergen challenge  by Weersink, E.J.M. et al.
Respiratory Medicine ( 1994) 88, 103-l 14 
Early and late asthmatic reaction after allergen 
challenge 
E. J. M. WEERSINK*, D. S. POSTMA*, R. AALBERS~ AND J. G. R. DE MONCHY~5 
*Department of Pulmonology, University Hospital, Groningen, The Netherlands; TDepartment of Allergology. 
University Hospital, Groningen, The Netherlands, and $Asthma Centre of The Netherlands, Davos CH, 
Switzerland 
Introduction 
In the early 1950s Herxheimer (1) clearly showed 
that two distinct components in the obstructive 
response to inhaled allergens could be discerned, 
which he named the immediate and late reaction. But 
it was not until the late 1960s before Pepys (2) and 
de Vries and coworkers (3) started to investigate the 
mechanisms of the immediate and late response to 
inhaled allergen by drug protection studies. Based on 
different effects of several drugs on the immediate 
and late reaction they concluded that different 
mechanisms must underlie these response patterns. It 
was suggested that the immediate reaction was due to 
constriction of the smooth airway muscles and the 
late reaction the result of inflammation. Gijkemeijer 
(4) showed that allergen challenge also leads to an 
increase in airway reactivity (AR). However, he 
found no relationship between the increase in AR 
and the immediate or late response. Then, Cockcroft 
et al. (5) demonstrated an increase in AR in associ- 
ation with the late allergic response (LAR). Later 
studies showed that subjects with an isolated EAR 
also develop an increase in AR, but to a much lesser 
extent than patients with a LAR (6). It has now 
generally been accepted that the increase in AR is 
usually associated with increased mucosal inflamma- 
tion of the airways (7). Therefore, it is intriguing that 
AR is already increased 3 h after allergen challenge, 
when the FEV, has returned to prechallenge values, 
thus even preceding the LAR. 
With the introduction of fibreoptic bonchoscopy, 
in recent years, broncho-alveolar lavage (BAL) and 
biopsies have become new research tools to study the 
cellular events in asthmatic airways after allergen 
challenge which can be investigated directly by 
microscopic studies including sophisticated immuno- 
histochemistry. 
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The present review includes a summary of recent 
developments in knowledge on the pathogenesis of 
the EAR and LAR. The focus is on the patho- 
physiological mechanisms of the EAR, LAR and 
associated AR. We will also discuss the different 
drugs that modulate the early and late reaction and 
the associated AR. 
Allergen inhalation 
Bronchial allergen challenge in sensitized atopic 
asthmatics results in bronchoconstriction that devel- 
ops within 10 min, reaches a maximum between 15 
and 30 min, and generally resolves within l-3 h. This 
period of bronchoconstriction is referred to as the 
early allergic response, which is defined as a fall in 
FEV, of 1 S-20% or more, or a fall of 40% or more in 
SGAW (8). Three to four or more hours after the 
onset of the EAR, a second period of bronchocon- 
striction may occur constituting the late allergic 
response (8). The duration of the LAR as measured 
with spirometry may be 12 h or even longer. 
Although the LAR need not be preceded by a 
clinically evident early response, isolated late reac- 
tions are rare in adults. This is in contrast with 
children where isolated late reactions are a frequent 
occurrence. 
Diurnal variation in airway tone and the effect of 
medication withdrawal may interfere with the detec- 
tion of the LAR, so this can be missed or not so 
pronounced (8). Hence, a control day, with saline 
challenge must be performed in that corrections for 
these confounders can be made [Fig. l(a) and (b)]. 
Pathophysiology of the asthmatic airways after 
allergen challenge 
INFLAMMATORY PROCESSES DURING THE EAR 
The exact mechanisms leading to immediate air- 
way narrowing after allergen challenge are still 
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Fig. I The effects after saline challenge on lung function (FEV,) on the control day (0) after allergen challenge on the 
provocation day (W) and on the provocation day corrected for control day (*). 
unclear. Traditionally, the EAR has been associated 
with the activation of pulmonary mast cells with 
subsequent release of preformed histamine, tryptase 
and de nova synthesis of spasmogenic products of the 
cycloxygenase pathway of arachidonic acid metabo- 
lism (PGD,, TxA,, along with products of the 
S-lipoxygenase pathway (leukotrienes) (9). Mast cells 
may be activated to secrete their mediators by a wide 
variety of mechanisms, the most familiar being the 
IgE-dependent process [high-affinity IgE (Fc,RI) 
receptor] (10). 
Alveolar macrophages generally have a suppressive 
effect, but this may be impaired in asthma after 
allergen exposure (11,12). The alveolar macrophage 
has even been incriminated in the EAR, being acti- 
vated by allergens via an IgE-dependent process 
[low-affinity IgE (Fc,RII) receptor] and releasing 
both acute phase and chemotactic mediators. These 
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Table I Effect of released inflammatory mediators after allergen inhalation 
Mediator 
Broncho- 
constriction 
Mucus 
secretion 
Microvascular 
leakage Chemotaxis Source 
Histamine + 
PGD, PGF,, + 
PGE, - 
TxA, + 
LTB, - 
L-E,, D,, E, + 
PAF + 
Kinins + 
Mast cell, Basophil 
Mast cell, Eosinophil 
Epithelial cell 
Epithelial cell 
Mast cell, Alv. macro. 
Alv. macro. 
Mast cell, Epithelial cell 
Eosinophil 
Alv. macro, Eosinophil 
Epithelial cell 
Mast cell 
acute phase products include the spasmogenic TxA,, 
TxB, LTB4 and PAF, as well as reactive oxygen 
species and lysosomal enzymes, which may lead to 
local tissue damage (13,14). In addition to alveolar 
macrophages, dendritic cells are also very effective 
antigen-presenting cells and may therefore play a 
very important role in the initiation of an allergen- 
induced response (11). Additionally, airway epithe- 
lium may also play a role in this process. After 
antigenic stimulation, epithelial cells are able to 
release LTC,, 12-HETE, PGE,, and PGF,, and 
chemotactic mediators such as LTB,, 15HETE and 
possibly PAF (15). 
The above mentioned inflammatory mediators 
have important bronchospasmogenic effects, next to 
their stimulatory role in mucus secretion, vasodila- 
tion, microvascular leakage and chemotaxis (Table 
1). These mediators may be at least responsible for 
the immediate clinical reaction after allergen chal- 
lenge. Moreover, release of chemotactic mediators 
by mast cells, alveolar macrophages, dendritic cells 
and epithelial cells may also be involved in the 
development of the LAR. More disputable is the 
role of T cells during the EAR. But after local 
allergen challenge a direct increase in CD4+ -cells 
was shown in BAL fluid. This provides evidence to 
support the role of T cells in this early state of the 
asthmatic response (16). 
INFLAMMATORY PROCESS BETWEEN THE EAR AND LAR 
The role of mast-cell-dependent products in the 
development of the late-phase inflammatory events 
after allergen challenge in atopic asthmatics is still 
controversial. Some studies have reported that 
release of mast-cell-associated high-molecular-weight 
neutrophil chemotactic factor (NCF) as well as 
eosinophil chemotactic factor (ECF) occurs during 
the EAR with a close relationship of NCF to the 
development of the ensuing LAR (17,18). The close 
relationship of NCF or ECF to the LAR may be 
relevant to the control of the mechanisms that govern 
the accumulation of eosinophils in the lung (19). 
More recently, it has become apparent that mast cells 
release, in an IgE-dependent fashion, an array of 
cytokines such as IL-3. IL-4, IL-5, GM-CSF. These 
cytokines have also been implicated in the patho- 
genesis of late-phase inflammatory events, especially 
in relation to eosinophils (2(X22). Although it has 
been suggested that one or more of the cytokines 
released by mast cells are in fact NCF or ECF, it 
should be pointed out that cytokine release does not 
start until 2 h after allergen challenge while NCF or 
ECF release occurs much earlier (17). Additionally, it 
should be recognized that most of the available data 
are derived from in vitro studies of murine mast cell 
lines. These results, therefore, can not be auto- 
matically applied to the human lung mast cell, but 
generally indicate that release of cytokines (IL-3, 
IL-4, IL-5 GM-CSF) or NCF and ECF by mast cells 
is relevant for the development of the LAR. It is 
known that IL-3, IL-5 and GM-CSF are involved in 
the control of eosinophil degranulation, activation of 
mature eosinophils in terms of increased cytotoxicity 
and oxidative metabolism and in prolonging eosino- 
phi1 survival in vitro (23). In bronchial lavage fluid 
and biopsies of the submucosa of asthmatics an 
increase of activated eosinophils is seen 34 h after 
allergen challenge, well before the late phase reaction 
(24,25). However, no release of cytotoxic eosinophil- 
mediator ECP is detected in BAL fluid at this point in 
time. Mast cells also release IL-4 which is involved 
in the survival and proliferation of T-helper cells, 
especially the T,2 phenotype (26). 
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Not only mast cells, but also alveolar macrophages 
release a diversity of cytokines. Human alveolar 
macrophages produce predominantly IL-1B. IL-l 
expression reaches its maximum 2-3 h after in vitro 
stimulation. Alveolar macrophages therefore, have 
the capacity to initiate an inflammatory response via 
the release of IL-l, which may activate T cells and 
dendritic cells are able to release IL-I as well (11). 
Human tracheal and bronchial epithelial cells are 
capable of synthesizing IL-l and TNF after allergen 
stimulation. IL-l and TNF may in turn induce 
the production of GM-CSF, IL-6 and IL-8 from 
epithelial cells (27). 
In addition to these cytokines, chemotactic factors 
(LTB,, 15-HETE, PAF) are liberated from mast cells, 
alveolar macrophages and epithelial cells. It is known 
that all of the above mentioned cytokines and chemo- 
tactic mediators can recruit, prime, and activate 
alveolar macrophages, T cells, neutrophils, eosino- 
phils and basophils, and can also increase immuno- 
globulin secretion (IgE of B cells) and regulate the 
proliferation of mast cells (Table 2). However, the 
exact mechanisms responsible for selective recruit- 
ment of inflammatory cells into the airway (sub)mu- 
cosa in allergic inflammation are not fully known. 
Cytokines are thought to play a role in this recruit- 
ment by upregulation of adhesion molecules for cells 
involved in the LAR (28,29). Three types of adhesion 
molecules have been observed on endothelial cells: 
ELAM-1 (endothelial leucocyte adhesion molecule- 
l), ICAM- (intracellular adhesion molecule-l) and 
VCAM- 1 (vascular cell adhesion molecule- 1). 
ELAM-1 is expressed on endothelial cells after stimu- 
lation with IL-l, TNF, and INF, and may be ex- 
pressed at sites of allergic inflammation (30). ICAM- 1 
is constitutionally expressed on endothelial cells and 
is markedly up-regulated in allergically inflamed tis- 
sue and after IL-l/?, TNF, and IFN, incubation (31). 
Endothelial expression of VCAM-I may be upregu- 
lated by IL-4 (32). It is intriguing that these cytokines, 
TNFa, IL-l and IL-4, which stimulate the expression 
of the appropriate adhesion molecules, are released 
by allergen triggered mast cells and other cells. 
This provides an important link between mast cell 
activation, upregulation of adhesion molecules, and 
subsequent T cell and eosinophil recruitment. 
After appropriate stimulation, ELAM-1 is maxi- 
mally expressed after 46 h, returning to baseline at 
24 h (30). ICAM- and VCAM-1 are expressed later, 
reaching a maximum at 24-48 h (31,32). It could be 
hypothesized that ELAM-1, which is maximally 
upregulated at the time of the LAR, is involved in the 
development of the LAR, whereas ICAM-I and 
VCAM-1 are not, but rather support the allergen- 
induced inflammatory process for a longer period 
of time. Furthermore, it is known that VCAM-1 
binds preferentially to specific adhesion molecules of 
eosinophils, whereas ELAM-1 and ICAM- bind to 
specific adhesion molecules of both eosinophils and 
neutrophils (25). 
Adhesion molecules are also expressed on leuco- 
cytes where they may act as specific ligands for the 
molecules described above. Three heterodimers have 
been described, consisting of a common P-chain 
(CDIS) and different a-chains LFA-1 (CD1 la), 
MAC-l (CDllb), and P150,95 (CDllc). CDlla,b,c, 
and CD18 act as specific ligands for ICAM- on 
endothelial cells. LFA-1 has been involved in T cell 
adhesion. All three heterodimers are involved to 
varying degrees in neutrophil, eosinophil, and mono- 
nuclear cell adhesion. More recently, it has been 
shown in vitro that recombinant IL-3 and recombi- 
nant GM-CSF selectively enhance basophil adhesive- 
ness to endothelial cells and expression of CD 11 b on 
this cell (33,34). Very late antigens (VLA) l-6 are yet 
another type of adhesion molecule on leucocytes. 
VLA-1 is expressed on activated T cells while VLA-4 
has only been detected on eosinophils adherent to 
VCAM-I on endothelium (32). Expression of these 
VLA adhesion molecules on leucocytes is observed 
6 h after allergen challenge. Although many of these 
findings were mainly obtained in in vitro studies, 
Wegner et al. (31) have shown that in Ascaris sensi- 
tized monkeys repeated allergen challenge caused an 
increase in ICAM- expression on both airway epi- 
thelium and submucosal endothelium, accompanied 
by eosinophilic infiltration of the mucosa and 
increased AR to methacholine. The latter two events 
were attenuated by intravenous infusion or inha- 
lation of a blocking anti-ICAM- monoclonal anti- 
body. These observations support the view that 
ICAM- plays an important role in the specific 
eosinophilic inflammatory response after allergen- 
inhalation. Although the kinetics of its upregulation 
in tissue suggest that this may be especially the case in 
chronic allergic inflammation. In addition to chemo- 
tactic signals released from allergically inflamed tis- 
sue, these adhesion mechanisms may be important in 
the generation of selective recruitment of circulating 
leucocytes into the airways (Fig. 2). 
INFLAMMATORY PROCESS DURING THE LAR 
The role of the T cell in the regulation and 
expression of airway inflammation in atopic asthma 
has been given considerable attention (35). IL-l, 
released by alveolar macrophages, dendritic and epi- 
thelial cells, regulates maturation and activation of T 
cells (CD3+). Such cells can be divided into two 
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Cell Released cytokines 
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Fig. 2 Effects of antigen stimulation on inflammatory cells during the EAR, important for the development of the LAR. 
major immunocytochemical and functional sub- 
groups, i.e. CD4 and CD8 cells. A decrease of CD4+ 
T cells and an increase in CD8 + T cells was shown in 
BAL fluid 6 h after allergen challenge of early 
responders. This is in contrast with dual responders, 
who showed an increase of CD4+ T cells and a much 
less pronounced increased in CD8+ T cells in BAL 
fluid (36). Recently, another study has reported that 
submucosal CDS+ T cells increased at 3 h and 24 h 
after allergen challenge by dual responders, and that 
appearance of these cells in biopsies correlated 
inversely with the severity of the LAR (37). The 
results of both studies provide evidence to support 
the hypothesis that CDS+ T cells may play a role in 
suppressing the LAR. 
CD4+ T cells (TH cells) are now recognized as 
important in allergic inflammatory responses. 
Antigen-activated T, cells can be divided into two 
functionally distinct subsets referred to as T,l and 
T,2, based on the pattern of cytokines secretion. T,l 
cells secrete only IL-2, INF,, TNF-P. T,2 cells 
secrete only IL-4, IL-5 and IL-6, which are thought 
to be involved in the cellular response during the 
LAR. In several studies (3840), a selective increase 
in T, cells in BAL fluid was observed 24 and 48 h 
after allergen challenge in those subjects who had 
previously been shown to develop a late-phase reac- 
tion. As these CD4+ T cells express positive hybrid- 
ization signals specifically for IL-4, IL-5, and G 
M-CSF, but not for IL-2, IL-3 and INF, after 24 h, 
this indicates a cytokine secretion profile of the T,2 
cell subtype upon allergen exposition (40,41). The 
same profile has been found in airway wall biopsies, 
showing an increase in mRNA expression for IL-5 
and GM-CSF (42). T,2-cell-derived IL-4 is inti- 
mately involved in the regulation of IgE production, 
as it stimulates and switches the immunoglobulin 
production of B cells to IgE in response to airborne 
allergens. Also, the survival and proliferation of T,2 
cells is dependent on IL-4. Other cytokines derived 
from T,2 such as IL-3, IL-5, GM-CSF, play a 
pivotal role in the activation, maturation and sur- 
vival of eosinophils. It is well known that eosinophils 
in BAL fluid-increase during the LAR in asthmatic 
patients (43). Subsequently, biopsies of the inflamed 
submucosa of the airway 24 h after allergen challenge 
has demonstrated an association between activated 
(EG2+) eosinophils and the number of IL-5 mRNA 
positive cells (42) and this coincides with an increase 
in ECP (24). It is known that preformed eosinophils 
products, such as ECP, MBP, EDN, and EPO are 
cytotoxic and neurotoxic and induce degranulation 
of mast cells and basophils (39,43,44). MBP and ECP 
are cytotoxic to epithelial cells of the airway in vitro 
and give rise to desquamation of the epithelial layer 
(45). As a consequence detachment of ciliated cells 
and destruction of individual cells may occur, leaving 
behind only basal cells at the epithelium lining (46). 
By others, it has been shown that this destruction 
leads to an increased incidence of tight junction 
openings of bronchial epithelium or widening in the 
intercellular space epithelium. This again was associ- 
ated with eosinophil infiltration (47). In addition to 
the release of basic proteins by activated eosinophils, 
other spasmogenic mediators such as LTC, PAF, 
PGE,,,, 15-HETE, TxB, and toxic oxygen-derived 
radicals are also released, which may induce an 
involvement in the allergic inflammatory process 
during the LAR (44). All these data support the role 
of the eosinophil as an important effector cell in this 
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process while T,2-cells are possibly important for the 
regulation of the allergic inflammation in the airways 
during the LAR. 
In addition to eosinophils, neutrophils have also 
been implicated in the LAR (43,44). The neutrophil 
may be recruited earlier to sites of inflammation in 
the lung, but this trasient, soon giving way to an 
eosinophilic infiltration. 
. Basophils may be also important during the late 
phase reaction, since tissue basophilia is found 6 h 
after allergen challenge (45). IL-3 and GM-CSF 
activate basophils leading to release of histamine. 
In conclusion, T cells become activated during, and 
perhaps even before, the late phase reaction possibly 
as a consequence of IL-l and IL-4 release by mast 
cells and other cells. Activated T cells also release 
cytokines (IL-3, IL-5, GM-CSF) which are involved 
in the activation and survival of eosinophils, possibly 
also activating basophils and mast cells. The (pro)in- 
flammatory mediators liberated by these activated 
inflammatory cells have numerous activities, includ- 
ing induction of smooth muscle contraction, 
increased mucus secretion, vasodilation and 
increased vascular leakage resulting in tissue edema, 
all of which are histological features during the LAR. 
Allergen-induced dysfunction of the neural pathways 
Allergen-induced biphasic response may lead to 
impaired /I-adrenoreceptor function (48). Twenty- 
four hours after allergen challenge in asthmatics, 
/I-adrenoreceptor numbers were reduced by 20% 
while their function (as measured by c-AMP pro- 
duction) was diminished by 40%. These changes, 
measured in lymphocyte membranes, are the result 
of uncoupling and downregulation of the 
/I-adrenoreceptor. An in vitro study showed that 
preincubation of peripheral blood lymphocytes with 
IL-l, IL-2, IFN, and GM-CSF for 20 h diminished 
c-AMP production (49). These findings suggest that a 
defect in /I-adrenoreceptor function and a decrease in 
numbers of peripheral blood lymphocytes may be the 
consequence of allergen challenge, possibly caused by 
cytokine release, from allergen-triggered cells in the 
airways. 
There are indications that parasympathetic inhibi- 
tory muscarinic,-receptors dysfunction may occur in 
asthmatics, resulting in exaggerated cholinergic reflex 
response. This has been observed after allergen chal- 
lenge and may contribute to the severity of the airway 
obstruction and increase in AR after the LAR, by 
increased release of acetylcholine (50,51). 
In addition to these neural systems human 
airways are also innervated by a noncholinergic 
nonadrenergic-system (NANC) of which the 
inhibitory-NANC system releases neuropeptides such 
as vasoactive intestinal peptide (VIP) and nitrous- 
oxide (NO) which are bronchodilatory. I-NANC 
activities can be impaired in animals after allergen 
challenge and this dysfunction may be due to 
associated protease release by mast cells (52). 
Overall these data suggest that allergen challenge 
results in a dysfunction of several neural regulating 
systems of the airways which contributes to 
bronchoconstriction and increased AR. Their exact 
role in humans is as yet however not fully clear. 
Allergen-induced airway reactivity 
Allergen-induced increase in non-specific AR has 
recently been shown to be present even before the 
LAR and is sustained for many days (5,44,53). 
Histamine and methacholine are normally used to 
measure allergen-induced AR and are more or less 
direct stimuli for smooth muscle contraction. This 
increase of non-specific AR, as measured by direct 
stimuli, is possibly the result of allergen induced 
decrease in the geometric diameter of the airways 
which could be caused by the airway wall oedema, 
vasodilation resulting in thickening of the wall and 
smooth muscle contraction. Indirect stimuli are 
also used to measure increases in AR, such as 
S-adenosine-monophosphate (AMP) and bradykinin 
(BK). One study compared methacholine with AMP 
and showed only an increase in AR to AMP 3 h after 
the allergen provocation, but not after 24 h, in con- 
trast with AR to methacholine which is increased at 
both time-points (6). This finding with AMP may 
be due to either mast cell depletion after allergen 
challenge or descensitization of prejunctional 
AZ-receptors on cholinergic nerve endings during the 
LAR (5456). Airway reactivity to BK was higher 
than for methacholine at 8 h and 3 weeks after 
allergen provocation (57). This increase at 8 h after 
the provocation is thought to be due to allergen- 
induced irritability of sensory nerves endings, 
whereas the sustained increase in AR to BK could be 
a consequence of slow epithelial repair. 
The mechanisms underlying allergen-induced 
increase in non-specific AR are not fully known, 
but it is likely that activated eosinophils, mast 
cells and their mediators may play an important 
role. Allergen-triggered mast cells give a release of 
leukotrienes and PGD,. Inhalation of LTC,, LTD,, 
and LTE, has been shown to enhance histamine 
reactivity of human asthmatic airways 4 h after 
leukotriene inhalation (58). This is also the case for 
PGD,, which gives an increase in AR to inhaled 
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histamine and methacholine in asthmatic subjects 
(59). It is known that activated eosinophils are 
increased 3 and 24 h after allergen challenge in BAL 
fluid and biopsies (25,424l). These allergen- 
induced changes in eosinophil numbers correlate 
with the increase in AR. Activated eosinophils 
release leukotrienes (LTC,, LTD,, LTEJ and PAF. 
The latter can induce acute (within 15 min) and 
persistent (as long as 7 days) increases in non- 
specific AR as measured with methacholine (60). 
Thus, leukotrienes and PGD,, released directly in 
human airways after allergen challenge, have the 
potential to increase AR to other constrictor medi- 
ators. Thus these mediators could be important for 
the increase in AR already at 3 h. 
Additionally, PAF is a chemotactic factor for 
eosinophils and activates these cells resulting in 
release of basic proteins, which are cytotoxic to the 
airway epithelium. A recent study demonstrated that 
damage to the bronchial epithelium is correlated with 
more severe AR, and the authors hypothesized that 
this could be the result of exposing sensory nerves in 
the airway and depriving the airway of epithelium 
derived relaxing factors (47). Stimulation of these 
sensory nerves by inflammatory mediators such as 
histamine, prostaglandins, PAF, leukotrienes and 
bradykinin, known to be liberated during the EAR 
and LAR, can result in the release of many neuro- 
peptides via a neural reflex. These neuropeptides of 
excitatory or E-NANC system may produce many 
of the pathophysiologic features of asthma. For 
instance, neurokinine A (NRA) is a very potent 
constrictor of human airways and enhances cholin- 
ergic neurotransmission. Substance P (SP) is a 
vasodilator, causes microvascular leakage and stimu- 
lates mucus secretion from submucosal glands and 
goblet cells. Calcitonin-gene related peptide (CGRP) 
is a potent and long-lasting vasodilator (61). These 
peptides may act on mast cells and other migratory 
cells. These neuropeptides are catabolized by neuro- 
endopeptidase (derived from airway epithelial cells) 
and this counter-regulation is therefore decreased 
after shedding of the epithelium. I-NANC system 
neuropeptides such as VIP and NO are catabolized 
by tryptase released from mast cells in allergically 
inflamed tissue (62). It can thus by hypothesized that 
release of neuropeptides and increase in irritability of 
sensory nerves after shedding of airway epithelium 
is the underlying pathophysiology mechanism to 
increase AR when it is sustained for days. 
In considering parameters of airway reactivity, it is 
important to distinguish between the position of the 
dose-response curve to a non-specific stimulus and 
the presence of a plateau in the curve, both which 
may be multicausally determined. It has been shown 
that allergen challenge, causing a dual response but 
not a single response, not only shifts the methacho- 
line dose-response curve to the left but also increases 
the maximal airway narrowing or even causes a loss 
of the plateau of the curve 24 h after the exposure 
(63). This suggests that airway inflammation also is 
important for increase in maximal airway narrowing. 
It can be concluded that the release of inflammatory 
mediators gives submucosal oedema, increases in 
mucus secretion and shedding of the epithelium, 
which may directly influence neural reflex-pathways, 
resulting in an increase in more AR as well as 
enhance of maximal airway narrowing. Loss of the 
plateau in the dose-response curve for methacholine 
or histamine is associated with excessive airway 
narrowing, which is a characteristic feature in 
asthma (64). 
Effect of drugs on the EAR and LAR 
In order to better understand the mechanisms 
underlying the EAR and LAR, several studies with 
drugs modulating inflammatory mediators or neural 
pathways have been performed. As histamine is 
thought to be a prime candidate bronchoconstrictor 
during the EAR, antihistamines have been investi- 
gated. In fact only terfenadine partially protected the 
EAR whereas azelastine and cetirizine had no effect 
(6566). This does, however, not exclude a role for 
histamine in the EAR, as it might well be that these 
oral drugs do not give adequate tissue levels in the 
airways. This notion is supported by the discrepancy 
between inhaled /I-adrenoceptor drugs that provide 
protection against histamine provocation and oral 
/3-adrenoceptor drugs that do not. As the cyclo- 
oxygenase inhibitor flurbiprofen is capable of reduc- 
ing the LAR, but not the EAR, prostaglandins may 
have a prominent role during the LAR (65). A role 
for leukotrienes during the EAR is supported by a 
protective study with leukotriene-antagonists and a 
leukotriene synthethase inhibitor (67,68). Moreover, 
the reduction of urinary LTE, production was 
associated with a decrease of the EAR. An animal 
study showed that microvascular leakage was even 
more reduced than smooth muscle contraction by 
a leukotriene-antagonist (69). Effects of PAF- 
anatagonists have been studied as well. While in 
animal studies, an inhaled PAF-antagonist reduced 
the LAR and the associated AR, no effect of an oral 
antagonist has been shown in humans (70,71). These 
results suggest a role for PAF during the LAR and in 
the induction of AR, nevertheless no effect was found 
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by an oral antagonist, so a role in humans is till open 
for question. 
In addition to drugs which target one mediator, 
there are drugs with a more general mechanism, such 
as glucocorticosteroids, sodium cromoglycate, 
nedocromil sodium, and xanthine derivatives. A 
single dose of oral or inhaled corticosteroids before 
allergen challenge inhibits the LAR and the induced 
AR, but has no effect on the EAR. However, after a 
continuous treatment for several weeks, a reduction 
of the EAR, LAR and associated AR was observed 
(3,72,73). Protection studies with single dose sodium 
cromoglycate and nedocromil sodium show a signifi- 
cant reduction of the allergen-induced early-, and late 
reaction and increase in AR (3,74). There are indi- 
cations of inhibitory effects of theophylline, especially 
the slow-release form, on the EAR, LAR and induced 
AR suggesting some anti-inflammatory properties in 
addition to their bronchodilating effects (7576). 
Conventional doses of bronchodilators such as 
terbutaline and salbutamol totally protect the EAR 
but not the LAR. However, a single high dose of 
salbutamol(2.5 mg) inhibits the EAR and LAR up to 
7 h after the allergen challenge as well as the allergen- 
induced AR (77). More recently, it has been shown 
that a single dose of the new long-acting &agonist, 
salmeterol, ablates the EAR and LAR and inhibits 
the associated AR for 34 h (78). The authors 
suggested that salmeterol has pharmacological effects 
on allergen-induced inflammatory responses in 
addition to its bronchodilator action. These data are 
in contrast with a protection study with salmeterol 
we recently performed (79). After corrections for the 
bronchodilator action of salmeterol, incomplete 
inhibition was found for both the EAR and LAR. 
While no protection from allergen-induced increase 
of AR after 24 h was observed. It might be argued 
that these effects can be explained by a sustained 
bronchodilator action and functional antagonism of 
&agonist rather than inhibiting of the allergen- 
induced late phase reaction. Formoterol also has an 
inhibitory effect on the EAR, LAR and induced AR 
for at least 12-24 h (80). However, only a reduction 
of the LAR and induced AR occurred and not a total 
ablation. A methodologically correct analysis of lung 
function following bronchodilation is necessary 
in order to separate the bronchodilatory and 
anti-inflammatory effect of these drugs. 
Conclusion 
Bronchial allergen challenge is a useful research 
tool for unravelling of the pathophysiology of 
bronchial asthma. The dynamics and mechanisms of 
the allergen-induced airway response can be studied 
by measuring physiologic parameters, variations in 
serum constituents and by the effect of pretreatment 
with various drugs. Since the introduction of the 
fibreoptic bronchoscope direct information on the 
local allergic inflammatory response can be obtained 
using broncho-alveolar lavage and (sub)mucosal 
biopsies. Airway resident and infiltrating cells 
involved in the EAR and LAR can be studied as well 
as their activation state and released mediators. 
Available data suggest that the fall in FEV, during 
the EAR is not only a consequence of bronchospasm, 
but also results from increased vascular permeability 
and oedema. In addition, the release of cytokines and 
chemo-attractive mediators from mast cells, alveolar 
macrophages, dendritic cells and epithelial cells may 
be important for the recruitment (via expression of 
adhesion molecules on endothelial cells and on circu- 
lating leucocytes) and activation of eosinophils and 
T-cells into the lung. The release of these cytokines 
may be essential for the development of the LAR, 
especially release of IL-l which activates TH cells. 
Additionally, evidence is accumulating that activa- 
tion of the eosinophil is also very important for the 
development of the LAR and the associated AR. 
This increased eosinophil activation may be initiated 
by the release of IL-3, IL-5 and GM-CSF by mast 
cells and T, cells, likely the T,2-subtypes. 
The release of many (pro)-inflammatory mediators 
by activated inflammatory cells and their effects on 
the neural system in the airways may account for the 
allergen-induced increase in AR. 
The well-known anti-inflammatory drugs, sodium 
cromoglycate, nedocromil sodium and glucocorti- 
costeroids, reduce or prevent both EAR and LAR 
and the allergen-induced AR. Conventional doses of 
short-acting &agonists protect the EAR, whereas 
high doses affect both EAR and LAR. However, 
long-acting &agonists inhibit both the EAR and 
LAR. It is not yet clear whether this is due to the 
sustained bronchodilating effect and functional 
antagonism or to a ‘real’ anti-inflammatory effect. 
Since specific antagonists and specific synthesis 
inhibitors of inflammatory mediators, have shown 
only partial inhibition of the EAR and/or LAR it 
is likely that no single mediator can account for 
the early and/or late phase reaction. The allergic 
asthmatic reaction and allergen-induced increase in 
AR, is orchestrated by many (pro-) inflammatory 
mediators released by allergen-triggered resident 
cells, airway epithelium and circulating cells selec- 
tively infiltrating the airways. Therefore, it may be 
more realistic to consider the EAR, LAR and 
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increase in AR as clinically measurable aspects of one 
and the same ongoing inflammatory process. 
bronchoalveolar lavage after local allergen challenge 
of asthmatic airways. Am Rev Respir Dis 1992; 145: 
1259-1264. 
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